The stock of Belite Bio Inc ADR (BLTE) has gone down by -22.25% for the week, with a -5.56% drop in the past month and a 31.00% rise in the past quarter. The volatility ratio for the week is 6.83%, and the volatility levels for the past 30 days are 7.95% for BLTE. The simple moving average for the past 20 days is -16.83% for BLTE’s stock, with a 28.13% simple moving average for the past 200 days.
Is It Worth Investing in Belite Bio Inc ADR (NASDAQ: BLTE) Right Now?
The 36-month beta value for BLTE is also noteworthy at -1.55. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The average trading volume of BLTE on November 27, 2024 was 62.73K shares.
BLTE) stock’s latest price update
Belite Bio Inc ADR (NASDAQ: BLTE)’s stock price has gone decline by -15.03 in comparison to its previous close of 75.34, however, the company has experienced a -22.25% decrease in its stock price over the last five trading days. seekingalpha.com reported 2024-11-12 that Belite Bio, Inc. (NASDAQ:BLTE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Tom Lin – Chairman and Chief Executive Officer Hendrik Scholl – Chief Medical Officer Nathan Mata – Chief Scientific Officer Hao-Yuan Chuang – Chief Financial Officer Conference Call Participants Basma Radwan – Leerink Partners Jennifer Kim – Cantor Yi Chen – H.C. Wainwright Michael Okunewitch – Maxim Group Operator Hello, and thank you for joining us to discuss Belite Bio’s Third Quarter 2024 Financial Results.
Analysts’ Opinion of BLTE
Many brokerage firms have already submitted their reports for BLTE stocks, with Maxim Group repeating the rating for BLTE by listing it as a “Buy.” The predicted price for BLTE in the upcoming period, according to Maxim Group is $60 based on the research report published on December 14, 2023 of the previous year 2023.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see BLTE reach a price target of $43. The rating they have provided for BLTE stocks is “Overweight” according to the report published on July 28th, 2023.
SVB Securities gave a rating of “Outperform” to BLTE, setting the target price at $25 in the report published on July 26th of the previous year.
BLTE Trading at 0.99% from the 50-Day Moving Average
After a stumble in the market that brought BLTE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.01% of loss for the given period.
Volatility was left at 7.95%, however, over the last 30 days, the volatility rate increased by 6.83%, as shares sank -8.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +31.95% upper at present.
During the last 5 trading sessions, BLTE fell by -22.25%, which changed the moving average for the period of 200-days by +33.51% in comparison to the 20-day moving average, which settled at $76.98. In addition, Belite Bio Inc ADR saw 39.93% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BLTE starting from Wei-Cheng Liaw, who proposed sale 5,999 shares at the price of $82.53 back on Nov 20 ’24. After this action, Wei-Cheng Liaw now owns shares of Belite Bio Inc ADR, valued at $495,097 using the latest closing price.
Nathan Mata, the Affiliate of Belite Bio Inc ADR, proposed sale 30,000 shares at $82.34 during a trade that took place back on Nov 19 ’24, which means that Nathan Mata is holding shares at $2,470,200 based on the most recent closing price.
Stock Fundamentals for BLTE
The total capital return value is set at -0.31. Equity return is now at value -40.04, with -38.10 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 24.76.
Conclusion
In summary, Belite Bio Inc ADR (BLTE) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
